Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Citius Oncology, Inc.NASDAQ: CTOR
Net Income · Q2 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q2 FY2026 net income of $26.61M (cash outflow) rose 244.0% year over year, ahead of the +14.7% change in trailing-twelve-month net income. Sequentially, it rose 380.8% from the prior quarter.
Context
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$38.1M (+53.9%) for the fiscal year ending Sep 2026, a step up from the +17.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.61M+380.8% QoQ
- Last fiscal yearSep 2025
- -$24.76M+17.1% YoY
- LTMMar 2026
- -$42.51M+14.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +244.0% | -25.5% | -269.5 pp |
| 1 year | +17.1% | +53.9% | +36.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (24.76M) USD
- Year-over-year change
- -17.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (24.76M) | -17.1% |
| FY2024 | 2024-09-30 | (21.15M) | -974.2% |
| FY2023 | 2023-09-30 | 2.42M | +535.3% |
| FY2022 | 2022-09-30 | 380.81K | — |
Net Income vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 net income of $42.51M is the 7th largest of the 10 companies compared; the peer median is $46.9M.
- Its year-over-year change of +14.7% is the 7th highest of 10, against a peer median of +121.2%.
- Net income amounts to 757.6% of revenue for CTOR, versus a peer median of 583.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $883.08M | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $380.63M | +410.8% | +148.5% | 1124.1% | |
| LTM Mar 2026 | $129.91M | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $75.86M | +73.5% | +71.0% | — | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $46.04M | +260.1% | -21.4% | 43.0% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $42.51M | +14.7% | — | 757.6% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| LTM Mar 2026 | $11.98M | +121.2% | +19.8% | 20.8% | |
| Peer median (excluding CTOR) | $46.9M | +121.2% | +19.8% | 583.5% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Net Income | 380.81K | 2.42M | (21.15M) | (24.76M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 576K | 1.06M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 64.24K | 411.77K | 13.2M | 9.89M |
| Accounts Receivables | 25.99K | 349.05K | 0 | 0 |
| Inventory | 0 | 0 | (2.13M) | (12.65M) |
| Accounts Payables | 0 | 0 | 2.42M | 9.52M |
| Other Working Capital | 38.25K | 62.72K | 12.91M | 13.02M |
| Other Non-Cash Items | (493.02K) | (3.43M) | 7.5M | 8.32M |
| Operating Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
| Capital Expenditures | 0 | 4 | (4) | (4) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (67.32M) | (1.32M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (5M) | (5.75M) |
| Investing Cash Flow | (67.32M) | (1.32M) | (5M) | (5.75M) |
| Debt Repayment | 0 | 0 | 3.8M | 0 |
| Common Stock Issued | 68.04M | 0 | 0 | 15.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (383.84K) | 1.66M | 1.07M | 0 |
| Financing Cash Flow | 67.66M | 1.66M | 4.87M | 15.17M |
| Effect of Forex Changes | 0 | 0 | (32.75K) | 0 |
| Net Change in Cash | 289.18K | (256.43K) | (32.63K) | 3.92M |
| Free Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.